Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316637 | 1.00 | AKT1 (0.36) | AKT1ALDH1A1GAAMAPTTNKS2 | |
| SCHEMBL316636 | 1.00 | AKT1 (0.36) | AKT1ALDH1A1GAAMAPTTNKS2 | |
| SCHEMBL313658 | 0.88 | HSD11B1 (0.41) | AKT1ALDH1A1TNKS2AVPR1AHPGD | |
| SCHEMBL313982 | 0.88 | OPRD1 (0.37) | AKT1ALDH1A1GAATNKS2AVPR1A | |
| SCHEMBL313657 | 0.88 | HSD11B1 (0.41) | AKT1ALDH1A1TNKS2AVPR1AHPGD | |
| SCHEMBL313981 | 0.88 | OPRD1 (0.37) | AKT1ALDH1A1GAATNKS2AVPR1A | |
| SCHEMBL313983 | 0.88 | OPRD1 (0.37) | AKT1ALDH1A1GAATNKS2AVPR1A | |
| SCHEMBL313656 | 0.88 | HSD11B1 (0.41) | AKT1ALDH1A1TNKS2AVPR1AHPGD | |
| SCHEMBL1810709 | 0.87 | AKT1 (0.48) | AKT1GAATNKS2AVPR1A | |
| SCHEMBL1810707 | 0.87 | AKT1 (0.48) | AKT1GAATNKS2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306042-A1 | Triazole Derivatives | TGFBR1, TGFBR2, SMAD3 | AKT1 457/4885ALDH1A1 2295/4885GAA 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.